Back to Search Start Over

Gene expression imputation provides clinical and biological insights into treatment-resistant schizophrenia polygenic risk.

Authors :
Prohens L
Rodríguez N
Segura ÀG
Martínez-Pinteño A
Olivares-Berjaga D
Martínez I
González A
Mezquida G
Parellada M
Cuesta MJ
Bernardo M
Gassó P
Mas S
Source :
Psychiatry research [Psychiatry Res] 2024 Feb; Vol. 332, pp. 115722. Date of Electronic Publication: 2024 Jan 05.
Publication Year :
2024

Abstract

Genome-wide association studies (GWAS) have revealed the polygenic nature of treatment-resistant schizophrenia TRS. Gene expression imputation allowed the translation of GWAS results into regulatory mechanisms and the construction of gene expression (GReX) risk scores (GReX-RS).  In the present study we computed GReX-RS from the largest GWAS of TRS to assess its association with clinical features. We perform transcriptome imputation in the largest GWAS of TRS to find GReX associated with TRS using brain tissues. Then, for each tissue, we constructed a GReX-RS of the identified genes in a sample of 254 genotyped first episode of psychosis (FEP) patients to test its association with clinical phenotypes, including clinical symptomatology, global functioning and cognitive performance. Our analysis provides evidence that the polygenic basis of TRS includes genetic variants that modulate the expression of certain genes in certain brain areas (substantia nigra, hippocampus, amygdala and frontal cortex), which at the same time are related to clinical features in FEP patients, mainly persistence of negative symptoms and cognitive alterations in sustained attention, which have also been suggested as clinical predictors of TRS. Our results provide a clinical explanation of the polygenic architecture of TRS and give more insight into the biological mechanisms underlying TRS.<br />Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: M. Bernardo has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Angelini, Casen Recordati, Janssen-Cilag, Menarini, Rovi and Takeda. The rest of the authors reported no biomedical financial interests or potential conflicts of interest.<br /> (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1872-7123
Volume :
332
Database :
MEDLINE
Journal :
Psychiatry research
Publication Type :
Academic Journal
Accession number :
38198858
Full Text :
https://doi.org/10.1016/j.psychres.2024.115722